Oncology Central

Novel small molecule inhibitors of the OLIG2 transcription factor: promising new therapeutics for glioblastoma


Approximately 10,000 new cases of glioblastoma (GBM) are diagnosed each year in the USA [1]. Most treatments are palliative in nature and do not alter the prognosis for the disease [2]. As a result, the median survival time is only about 15 months [3]. Even after extensive surgery to debulk the tumor, chemotherapy and radiation, the tumors invariably recur due to residual tumor-propagating cells that have been described as glioma stem-like cells (GSCs) [4,5].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.